{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:24:48Z","timestamp":1774437888824,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40265-019-01133-w","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:17:07Z","timestamp":1558567027000},"page":"997-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Tiotropium\/Olodaterol: A Review in COPD"],"prefix":"10.1007","volume":"79","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"1133_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019. \n                    http:\/\/goldcopd.org\/gold-reports\/\n                    \n                  . Accessed 7 May 2019."},{"key":"1133_CR2","unstructured":"Boehringer Ingelheim. Stiolto\u00ae Respimat\u00ae (tiotropium bromide and olodaterol): US prescribing information; 2018. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 7 May 2019."},{"key":"1133_CR3","unstructured":"Pharmaceuticals and Medical Devices Agency. Spiolto Respimat 28 puffs \/ Spiolto Respimat 60 puffs: Japanese prescribing information; 2015. \n                    http:\/\/www.pmda.go.jp\n                    \n                  . Accessed 7 May 2019."},{"key":"1133_CR4","unstructured":"National Drug Administration Drug Evaluation Center. Tiotropium bromide olodaterol inhalation spray: Chinese prescribing information; 2018. \n                    http:\/\/202.96.26.102\/\n                    \n                  . Accessed 7 May 2019."},{"key":"1133_CR5","unstructured":"European Medicines Agency. Spiolto\u00ae Respimat\u00ae (tiotropium bromide and olodaterol): summary of product characteristics; 2018. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 7 May 2019."},{"issue":"6","key":"1133_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-015-0371-4","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75(6):665\u201373.","journal-title":"Drugs"},{"issue":"15","key":"1133_CR7","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s40265-014-0307-4","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Tiotropium Respimat\u00ae Soft Mist\u2122 inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801\u201316.","journal-title":"Drugs"},{"issue":"1","key":"1133_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40265-015-0527-2","volume":"76","author":"S Dhillon","year":"2016","unstructured":"Dhillon S. Tiotropium\/olodaterol: a review in COPD. Drugs. 2016;76(1):135\u201346.","journal-title":"Drugs"},{"issue":"4","key":"1133_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"issue":"10","key":"1133_CR10","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"key":"1133_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pupt.2015.04.002","volume":"32","author":"KM Beeh","year":"2015","unstructured":"Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1133_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/COPD.S95055","volume":"11","author":"KM Beeh","year":"2016","unstructured":"Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat\u00ae is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler\u00ae (ENERGITO\u00ae study). Int J Chron Obstruct Pulmon Dis. 2016;11(1):193\u2013205.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"1133_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","volume":"6","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337\u201344.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1133_CR14","doi-asserted-by":"publisher","first-page":"1601348","DOI":"10.1183\/13993003.01348-2016","volume":"49","author":"DE O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium\/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348.","journal-title":"Eur Respir J"},{"key":"1133_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1753465818755091","volume":"12","author":"F Maltais","year":"2018","unstructured":"Maltais F, O\u2019Donnell D, Galdiz Iturri JB, et al. Effect of 12 weeks of once-daily tiotropium\/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1\u201313.","journal-title":"Ther Adv Respir Dis"},{"issue":"8","key":"1133_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1164\/rccm.201706-1288OC","volume":"198","author":"T Troosters","year":"2018","unstructured":"Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"1133_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02049-2018","author":"F Maltais","year":"2019","unstructured":"Maltais F, Aumann JL, Kirsten AM, et al. Dual bronchodilation with tiotropium\/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019. \n                    https:\/\/doi.org\/10.1183\/13993003.02049-2018\n                    \n                  .","journal-title":"Eur Respir J"},{"issue":"1","key":"1133_CR18","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/COPD.S108758","volume":"11","author":"GT Ferguson","year":"2016","unstructured":"Ferguson GT, Karpel JP, Clerisme-Beaty E, et al. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO\u00ae and OTEMTO\u00ae studies: a subgroup analysis by age. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2701\u201310.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1133_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","volume":"32","author":"GT Ferguson","year":"2015","unstructured":"Ferguson GT, Flezar M, Korn S, et al. Efficacy of tiotropium plus olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32(6):523\u201336.","journal-title":"Adv Ther"},{"issue":"6","key":"1133_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.chest.2018.01.008","volume":"153","author":"F Maltais","year":"2018","unstructured":"Maltais F, Buhl R, Koch A, et al. \u03b2-Blockers in COPD: a cohort study from the TONADO research program. Chest. 2018;153(6):1315\u201325.","journal-title":"Chest"},{"key":"1133_CR21","doi-asserted-by":"crossref","unstructured":"Buhl R, Derom E, Bjermer L, et al. Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and\/or emphysema [abstract no. PA979]. Eur Respir J. 2016;48(Suppl 60).","DOI":"10.1183\/13993003.congress-2016.PA979"},{"key":"1133_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-016-0387-7","volume":"17","author":"D Singh","year":"2016","unstructured":"Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO\u00ae studies. Respir Res. 2016;17:73.","journal-title":"Respir Res"},{"key":"1133_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/COPD.S179912","volume":"14","author":"FJ Martinez","year":"2019","unstructured":"Martinez FJ, Abrahams RA, Ferguson GT, et al. Effects of baseline symptom burden on treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:181\u201394.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1133_CR24","doi-asserted-by":"crossref","unstructured":"Derom E, Beeh KM, Echave-Sustaeta J, et al. Tiotropium + olodaterol provides significant lung-function benefits compared to flucticasone + salmeterol regardless of prior bronchodilator use [abstract no. PA978]. Eur Respir J. 2017;48(Suppl 60).","DOI":"10.1183\/13993003.congress-2016.PA978"},{"issue":"1","key":"1133_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-016-0002-x","volume":"27","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7.","journal-title":"NPJ Prim Care Respir Med"},{"key":"1133_CR26","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.2147\/COPD.S137719","volume":"12","author":"C Bai","year":"2017","unstructured":"Bai C, Ichinose M, Lee SH, et al. Lung function and long-term safety of tiotropium\/olodaterol in East Asian patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:3329\u201339.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1133_CR27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2147\/COPD.S110389","volume":"11","author":"M Ichinose","year":"2016","unstructured":"Ichinose M, Taniguchi H, Takizawa A, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat\u00ae inhaler in patients with COPD: results from the Japanese sub-population of the Tonado\u00ae studies. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2017\u201327.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1133_CR28","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2147\/COPD.S169941","volume":"13","author":"M Ichinose","year":"2018","unstructured":"Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium\/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. Int J Chron Obstruct Pulmon Dis. 2018;13:2147\u201356.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1133_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2147\/COPD.S166023","volume":"13","author":"M Ichinose","year":"2018","unstructured":"Ichinose M, Minakata Y, Motegi T, et al. Efficacy of tiotropium\/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis. 2018;13:1407\u201319.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1133_CR30","doi-asserted-by":"crossref","unstructured":"Minakata Y, Motegi T, Ueki J, et al. Efficacy of tiotropium\/olodaterol on sedentary\/active time in COPD patients: VESUTO study [abstract no. PA4390]. Eur Respir J. 2018;52(Suppl 62).","DOI":"10.1183\/13993003.congress-2018.PA4390"},{"issue":"11","key":"1133_CR31","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s12325-017-0626-4","volume":"34","author":"GJ Feldman","year":"2017","unstructured":"Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium\/vilanterol and tiotropium\/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518\u201333.","journal-title":"Adv Ther"},{"key":"1133_CR32","doi-asserted-by":"crossref","unstructured":"Valipour A, Tamm M, Kocianova J, et al. Improvement of self-reported physical functioning with tiotropium\/olodaterol in Central and Eastern European COPD patients [abstract no. PA912]. Eur Respir J. 2018;52.","DOI":"10.1183\/13993003.congress-2018.PA912"},{"key":"1133_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.rmed.2016.11.011","volume":"122","author":"R Buhl","year":"2017","unstructured":"Buhl R, Magder S, Bothner U, et al. Long-term general and cardiovascular safety of tiotropium\/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58\u201366.","journal-title":"Respir Med"},{"key":"1133_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rmed.2018.08.012","volume":"143","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Buhl R, Bothner U, et al. Safety of tiotropium\/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir Med. 2018;143:67\u201373.","journal-title":"Respir Med"},{"issue":"2","key":"1133_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.resinv.2016.09.004","volume":"55","author":"M Ichinose","year":"2017","unstructured":"Ichinose M, Kato M, Takizawa A, et al. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2017;55(2):121\u20139.","journal-title":"Respir Investig"},{"issue":"5","key":"1133_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bcp.12545","volume":"79","author":"D Singh","year":"2015","unstructured":"Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695\u2013708.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1133_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181\u201396.","journal-title":"Chest"},{"issue":"2","key":"1133_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1753465815624612","volume":"10","author":"M Schlueter","year":"2016","unstructured":"Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89\u2013104.","journal-title":"Ther Adv Respir Dis"},{"key":"1133_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41030-017-0048-0","volume":"3","author":"KYJ Sion","year":"2017","unstructured":"Sion KYJ, Huisman EL, Punekar YS, et al. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting \u03b22-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3:297\u2013316.","journal-title":"Pulm Ther"},{"key":"1133_CR40","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/COPD.S146338","volume":"12","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Matera MG, Ora J, et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469\u201385.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"1133_CR41","doi-asserted-by":"publisher","first-page":"1601794","DOI":"10.1183\/13993003.01794-2016","volume":"49","author":"M Molimard","year":"2017","unstructured":"Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794.","journal-title":"Eur Respir J"},{"key":"1133_CR42","first-page":"145","volume":"4","author":"RN Dalby","year":"2011","unstructured":"Dalby RN, Eicher J, Zierenberg B. Development of Respimat\u00ae Soft Mist\u2122 Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145\u201355.","journal-title":"Med Devices (Auckl)"},{"key":"1133_CR43","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2147\/PPA.S82857","volume":"10","author":"PN Dekhuijzen","year":"2016","unstructured":"Dekhuijzen PN, Lavorini F, Usmani OS. Patients\u2019 perspectives and preferences in the choice of inhalers: the case for Respimat\u00ae or HandiHaler\u00ae. Patient Prefer Adherence. 2016;10:1561\u201372.","journal-title":"Patient Prefer Adherence"},{"key":"1133_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.rmed.2018.10.006","volume":"144","author":"MVC Oliveira","year":"2018","unstructured":"Oliveira MVC, Pizzichini E, da Costa CH, et al. Evaluation of the preference, satisfaction and correct use of Breezhaler\u00ae and Respimat\u00ae inhalers in patients with chronic obstructive pulmonary disease\u2014INHALATOR study. Respir Med. 2018;144:61\u20137.","journal-title":"Respir Med"},{"issue":"1","key":"1133_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/jamp.2011.0941","volume":"26","author":"Y Asakura","year":"2013","unstructured":"Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching tiotropium HandiHaler\u00ae to Respimat\u00ae Soft Mist Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41\u20135.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1133_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/COPD.S91118","volume":"11","author":"M Miravitlles","year":"2016","unstructured":"Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:407\u201315.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1133_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/COPD.S190639","volume":"14","author":"R Dhand","year":"2019","unstructured":"Dhand R, Eicher J, Hansel M, et al. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chron Obstruct Pulmon Dis. 2019;14:509\u201323.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1133_CR48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/CEOR.S116546","volume":"8","author":"A Tebboth","year":"2016","unstructured":"Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016;8:667\u201374.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1133_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/COPD.S191031","volume":"14","author":"M Hoogendoorn","year":"2019","unstructured":"Hoogendoorn M, Corro Ramos I, Baldwin M, et al. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. Int J Chron Obstruct Pulmon Dis. 2019;14:447\u201356.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"1133_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/1753465816657272","volume":"10","author":"C Selya-Hammer","year":"2016","unstructured":"Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat\u00ae fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391\u2013401.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"1133_CR51","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.2147\/COPD.S114738","volume":"11","author":"JF van Boven","year":"2016","unstructured":"van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2191\u2013201.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"updated-by":[{"DOI":"10.1007\/s40265-019-01172-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01133-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01133-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01133-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:32:31Z","timestamp":1590017551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01133-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01133-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-019-01172-3","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"22 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Tiotropium\/Olodaterol: A Review in COPD, written by Hannah.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}